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S ystemic capillary leak syndrome (SCLS) is a rare but life-threatening disorder ﬁrst described 
by Clarkson et al.  in 1960[1].  There have been sev-
eral reports on SCLS and potentially eﬀective treat-
ments including ﬂuid resuscitation [1-12],  continuous 
renal replacement therapy [4,6],  low-dose corticoste-
roid treatment [1,2,4,8,12],  continuous inotrope 
infusion [1,3,6-8,11,12],  high-dose intravenous 
immunoglobulin (IVIG) therapy [9,11],  pulse cortico-
steroid treatments [4-6],  and plasma exchange (PE) 
treatments [10].  Although the etiology of SCLS is 
still unclear,  many reports have suggested that some 
kind of autoimmune pathway is implicated in the 
pathology of this disease [9,13].  Of those treatments,  
steroids,  IVIG therapy,  and PE have the potential to 
induce resolution through immunomodulation.
　 Here we report the case of a patient with SCLS 
alongside therapy-refractory shock after an emergency 
cesarean section,  who recovered after the initiation of 
PE.  Consent for publication was obtained directly 
from the patient.
Case Report
　 The patient was a 32-year-old woman pregnant with 
twins.  She had been previously healthy and had one 
healthy daughter.  She had no problems with the cur-
rent pregnancy until gestational week 27.  Her chief 
complaint then was general fatigue,  and she was 
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A 32-year-old woman,  pregnant with twins,  presented with a chief complaint of general fatigue.  Her 
general condition had rapidly deteriorated since her last visit to the primary obstetrician; the patient 
was then referred to our hospital because of suspected fetal death.  She underwent emergency cesar-
ean section because fetal death had indeed occurred,  and she was then admitted to the intensive care 
unit (ICU).  On ICU admission,  she was found to be in shock.  Laboratory analysis revealed extreme 
hemoconcentration and a low albumin level,  and initially,  septic shock with obstetric complications 
was suspected.  However,  because she did not respond to conventional therapy but instead,  rapidly 
developed severe generalized edema,  systemic capillary leak syndrome (SCLS) was diagnosed.  The 
patient remained in shock for several days until undergoing plasma exchange (PE),  despite some ear-
lier empirical treatments.  She eventually recovered from profound shock status and was discharged 
from the ICU without sequelae.  Among potentially eﬀective treatments,  PE seemed to be the most 
reasonable choice for the treatment of her SCLS.
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referred to our hospital by her primary obstetrician 
because of suspected fetal death.  Admission labora-
tory data revealed extreme hemoconcentration (hemo-
globin 20.3 g/dL,  hematocrit 58.3 ),  low serum 
albumin (2.2 g/dL),  high lactate (5.5 mmol/L),  and 
compensated metabolic acidosis.  Because the twin 
fetuses had indeed already died in utero,  an emergency 
cesarean section was performed.  During surgery,  the 
obstetrician observed a mass-like region on her 
descending colon and called a general surgeon,  who 
suggested observational follow-up.  The cesarean sec-
tion was completed,  and the patient was then admitted 
to the intensive care unit (ICU).  Although the proce-
dure was successful,  her postsurgical condition rap-
idly deteriorated.  Initially,  septic shock accompanied 
by obstetrical complications was suspected,  and ther-
apy consisted of antibiotics (meropenem and clindamy-
cin on day 1,  meropenem and arbekacin on days 2–10),  
ﬂuid,  and vasopressors.  Continuous renal replace-
ment therapy was then initiated because of acute kid-
ney injury.  Laboratory data on admission to our hos-
pital and within the ﬁrst 10 days in the ICU are shown 
in Table 1.
　 Because the therapies administered had little eﬀect 
on the patientʼs clinical condition,  low-dose hydrocor-
tisone was administered for 3 days.  Despite this,  on 
ICU day 3,  the patient began to complain of dyspnea 
due to a large persistent pleural eﬀusion that resulted 
in intubation (Fig. 1).  The patient was sedated using 
fentanyl,  dexmedetomidine,  and midazolam.  Her white 
blood cell count remained high,  her hemoglobin 
remained concentrated,  and her albumin level stayed 
low despite 12.5–50 g of albumin administration for the 
ﬁrst 7 days.  The rapidly progressing generalized 
edema (Fig. 1),  persistent hemoconcentration,  and 
shock status,  despite the substantial ﬂuid administra-
tion,  led to the diagnosis of SCLS.  To identify an 
increase in monoclonal paraproteins,  we submitted a 
blood sample to immune electrophoresis on ICU day 4,  
which turned out to be negative 3 days later.  Even 
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ICU day 1 ICU day 2
Fig.  1　 Chest and abdominal computed tomography conﬁrmed 
rapid progressive bilateral pleural eﬀusions and ascites.  White 
arrows indicate bilateral pleural eﬀusions (upper ﬁgures) and an 
ascites (lower ﬁgures).
Table 1　 Laboratory data of ﬁrst 10 days in the ICU
ICU day
0 1 2 3 4 5 6 7 8 9 10
WBC (/µL) 42,700 59,100 65,600 45,700 32,100 42,600 45,000 42,700 30,600 29,400 19,400
Hct (%) 58.3 43.5 36.1 36.3 23.3 32.2 29.1 38.3 31.8 35.9 28.9
Alb (g/dL) 2.2 2.1 1.2 1.7 1.9 1.2 0.7 0.6 1.3 1.9 1.7
PCT (ng/mL) 11.4 18.2 16.6 20.3 11.6 6.9 6.7 5.7
CRP (mg/dL) 22.8 11.8 9.5 7.4 4.8 3.5 2.2 2.8 3.8 6.5 6.2
hCG (mIU/mL) 397 73.8
β-hCG (mIU/mL) 387 82.8
Estradiol (pg/mL) 419 400 252
CEA (ng/mL) 1.47 1.42
CA19-9 (U/mL) 2.4 11.9
CA125 (U/mL) 13.3
Immune electrophoresis No bands
ICU, intensive care unit; WBC, white blood cell; Hct, hematocrit; Alb, albumin; PCT, procalcitonin; CRP, C-reactive protein; hCG, 
human chorionic gonadotropin; CEA, carcinoembryonic antigen; CA, cancer antigen.
ICU day 0 represents the data on admission.　 
after the diagnosis was made,  we still suspected sep-
sis and obstetrical complications.  Obstetrical compli-
cations were considered highly unlikely due to the 
serum estradiol and β-human chorionic gonadotropin 
levels,  which were within normal post-delivery limits 
(Table 1).  The descending colon mass was also evalu-
ated using computed tomography (CT) and tumor 
markers.  On CT,  the mass looked like an invagina-
tion,  and the serum carcinoembryonic antigen,  cancer 
antigen 19-9,  and cancer antigen 125 levels were 
1.47 ng/mL,  2.4 U/mL,  and 13.3 U/mL,  respective-
ly; these were all within normal ranges.  Exploratory 
surgery was considered,  but ruled out due to the 
patientʼ poor physical status.  
　 On ICU day 3,  a continuous epinephrine infusion 
at 0.05 μg/kg/min was started,  but without any bene-
ﬁcial eﬀect.  IVIG (1 g/kg/day for 3 days; Venoglob-
ulin 5  IV; Mitsubishi Tanabe Pharma Corporation,  
Osaka,  Japan) was also initiated.  In addition,  pulse 
steroid therapy (methylprednisolone 10 mg/kg/day 
for 3 days) was initiated following the low-dose corti-
costeroid therapy.  However,  these therapies did not 
seem to aﬀect her status; the total amount of ﬂuid 
administration exceeded 10,000 mL/day.  On ICU day 
5,  although we had not obtained the immune electro-
phoresis results,  we decided to perform PE due to the 
severity and persistence of her condition.  PE was 
performed with 3,000 mL of fresh frozen plasma 
exchanged during 100-min procedures 3 days in a row.  
The amount of ﬂuid administered on the ﬁrst PE day 
was markedly reduced,  and her body weight,  which 
had been increasing,  began to plateau.  On ICU day 6,  
while undergoing the second PE,  her blood pressure 
considerably increased to a mean arterial pressure of
＞65 mmHg.  After the second PE,  her pulse pres-
sure widened,  blood pressure stabilized,  and shock 
status subsided.  The ICU course for the ﬁrst 10 days 
is shown in Fig. 2.
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Fig.  2　 The patient course for the ﬁrst 10 days in the intensive care unit (ICU) is shown in the upper panel.  The wide white downward 
arrows indicate when PE was performed.  On ICU day 6,  during the second PE,  her mean blood pressure increased to＞65 mmHg and her 
pulse pressure widened.  The lower two panels show ﬂuid in‒out balance and body weight.  ABP,  arterial blood pressure; HR,  heart 
rate; MPSL,  methylprednisolone.
　 After she recovered from the profound shock,  her 
status became more stable daily,  although it took sub-
stantial time to reduce her body weight.  However,  on 
ICU day 22,  fecal matter was discharged through the 
abdominal drain that had been placed in the surgical 
wound on ICU day 5 for preventing abdominal com-
partment syndrome.  The reason for the panperitonitis 
became apparent when a tumor-like mass,  detected on 
the ﬁrst CT scan and during the surgery,  was found 
to be a ruptured adenocarcinoma.  An emergency 
Hartmann procedure was performed.  Although a tra-
cheostomy was required for long-term respirator man-
agement on ICU day 29,  the remainder of the ICU 
course was unremarkable.  She made the transition 
from hemodiaﬁltration to hemodialysis on ICU day 44 
and was eventually withdrawn from hemodialysis on 
ICU day 52.  The tracheostomy was closed on ICU day 
62,  and she was discharged from the ICU on day 67.  
She has been undergoing chemotherapy for descending 
colon cancer since her ICU discharge and remains 
otherwise healthy at the time of this writing.
Discussion
　 SCLS is a rare syndrome ﬁrst reported by 
Clarkson et al.  [1].  Its etiology remains uncertain and 
its diagnosis is sometimes diﬃcult.  In the present 
case,  the salient points for diagnosis were hemocon-
centration and rapidly progressing generalized edema 
[1-14].  Increase in monoclonal paraproteins has been 
observed in approximately 76–89  of SCLS patients 
[3,13,14].  However,  no reports have conﬁrmed that 
monoclonal gammopathy was a pathogenic factor.  In 
this case,  we performed immune electrophoresis,  but 
bands were absent.  
　 The diﬀerential diagnosis included paraneoplastic 
syndrome associated with colon cancer,  sepsis,  and 
ovarian hyperstimulation syndrome.  Ovarian hyper-
stimulation syndrome was ruled out based on the 
patientʼs serum estradiol level.  Sepsis was not com-
pletely ruled out,  but we had never experienced sepsis 
with such dense hemoconcentration and severe gener-
alized edema.  There have been 2 previous case 
reports of SCLS associated with cancer [15,16],  and 
indeed,  paraneoplastic syndrome could not be com-
pletely ruled out as a pathogenic factor of SCLS in 
our patient.
　 In this case,  the patient exhibited markedly high 
white blood cell counts consisting mostly of neutro-
phils.  There have been reports showing an association 
between high serum granulocyte colony-stimulating 
factor (G-CSF) levels and SCLS [17-19]; in addi-
tion,  G-CSF is highly expressed in human colon can-
cer [20].  Although the serum G-CSF level was not 
measured in our patient,  she may have had a high 
serum G-CSF level that caused leukocytosis.  A 
reduction of G-CSF after PE might have contributed 
to the improvement of our patientʼs status.  Several 
previous reports focused on the prophylaxis of repet-
itive shock episodes [10-14],  but few have reported 
the details of therapeutic steps taken to relieve the 
critical,  profound shock.  PE seems to be a rare ther-
apeutic choice for reversing shock in SCLS.  There 
are almost no reports of its use for this indication 
during the past decade.  Kapoor et al.  [10] reported 
one case treated with PE,  but the report was lacking 
in details.  PE is believed to exert its immunomodula-
tory eﬀect by eliminating soluble proteins,  including 
molecules as large as 1,000–3,000 kDa [10].
　 Recently,  several reports have described the ther-
apeutic eﬃcacy of high-dose immunoglobulin adminis-
tration for the profound hypovolemic shock of SCLS 
[9,12].  The mechanisms by which IVIG exerts pre-
ventive eﬀects against hypervascular permeability are 
not fully understood,  but the eﬀect is suggested to be 
immunomodulation,  mainly owing to the production of 
cytokines and cytokine antagonists [22].  Lambert et 
al.  [9] reported that IVIG of 1 g/kg/day markedly 
reversed SCLS within 48 h.  We administered the 
same amount of immunoglobulins (1 g/kg/day or 
50 g/day) for 3 days without any remarkable eﬀect.  
Because,  in SCLS,  molecules as large as 900 kDa 
can leak through the vasculature [2],  it is possible 
that the administered IVIG also leaks into the extra-
vascular spaces and thus cannot exert beneﬁcial 
eﬀects.
　 In conclusion we report a patient with SCLS 
refractory to empirical therapies who immediately 
recovered after the commencement of PE therapy.  In 
light of the cost and safety,  PE should not be per-
formed too readily; however,  it may be considered 
when a patient is experiencing profound therapy-re-
fractory shock,  even though SCLS is generally con-
sidered to be a self-limited disease.
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